Find a Doctor or Practice Location

You can also search for providers and practices at Penn Medicine Lancaster General Health or Princeton Health.

within
I am searching for a
Reset Form
Adam D. Cohen, MD

Adam D. Cohen, MD Physician

Director, Myeloma Immunotherapy Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Cohen is employed by Penn Medicine.

About Dr. Adam D. Cohen

Recognized by America's Top Doctors for 2017

Recognized by Best Doctors in America 2016

Recognized in Philadelphia magazine's annual Top Docs issues for 2018 and 2019

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Clinical Specialties

Specialty:

  • Hematology

Programs & Centers:

Board Certification:

  • Hematology, 2002
  • Medical Oncology, 2005

Clinical Expertise:

  • Amyloidosis
  • Bone Marrow Biopsy
  • Immunotherapy
  • Light Chain Disorders
  • Monoclonal Gammopathy of Undetermined Significance
  • Plasma Cell Dyscrasia
  • POEMS Syndrome
  • Primary Systemic Amyloidosis
Show All Expertise

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: University of Pennsylvania School of Medicine
Residency: Hospital of the University of Pennsylvania
Fellowship: Memorial Sloan-Kettering Cancer Center

Memberships

American Association for Cancer Research, National American Society of Clinical Oncology, National American Society of Hematology, National Eastern Cooperative Oncology Group, National Independent Data and Safety Monitoring Committee, "Griffin" randomized trial of Daratumumab-RVD vs RVD for newly-diagnosed myeloma (NCT02874742), International International Myeloma Society, International International Myeloma Working Group (IMWG), International

Hospital Affiliation

Dr. Cohen is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

Cancer immunotherapy
Vaccines
Cellular therapy
Phase I trials
CAR T cells

Selected Publications:

Cohen, A D., Garfall, A L., Stadtmauer, E A., Melenhorst, J. J, Lacey, Simon F., Lancaster, E, Vogl, D T., Weiss, B M., Dengel, K, Nelson, A, Plesa, G, Chen, F, Davis, M M., Hwang, Wei-Ting, Young, R M., Brogdon, J L., Isaacs, R, Pruteanu-Malinici, I, Siegel, D L., Levine, B L., June, C H., Milone, M C.: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma The Journal of Clinical Investigation : doi: 10.1172/JCI126397,2019.

Susanibar Adaniya, S P., Cohen, A D.*, Garfall, A L.*: Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications American Journal of Hematology doi: 10.1002/ajh.25428 (0): 2019.

Pazina T, James AM, Colby KB, Yang Y, Gale A, Jhatakia A, Kearney A, Graziano RF, Bezman NA, Robbins MD, Cohen AD, Campbell KS.: Elotuzumab enhances SLAMF7 interactions between natural killer and multiple myeloma cells to co-stimulate cytotoxicity. Cancer Immunology Research : 2019.

Fajgenbaum DC, Langan R-A, Japp AS, Shilling D, Partridge HL, Pierson SK, Singh A, Ruth JR, Nabel CS, Stone K, Chaturvedi V, Okumura M, Schwarer A, Jose FF, Hamerschlak N, Wertheim GB, Cohen AD, Krymskaya V, Rubenstein A, Betts M, Kambayashi T, Jordan MB, van Rhee F, Uldrick TS.: P13K/Akt/mTOR is a Novel Therapeutic Target in IL-6-blockade Refractory iMCD. Journal of Clinical Investigation : 2019.

Cornell RF, Ky B, Weiss BM, Dahm C, Gupta DK, Du L, Carver JR, Cohen AD, Engelhardt BG, Garfall AL, Goodman SA, Harrell SL, Kassim AA, Jadhav T, Jagasia M, Moslehi J, O’Quinn R, Savona MR, Slosky D, Smith Am, Stadtmauer EA, Vogl DT, Waxman A, Lenihan D.: Prospective Study of Cardiac Events during Proteastome Inhibitor Therapy for Relapsed Multiple Myeloma. Journal of Clinical Oncology : 2019.

Cohen AD, Lendvai N, Nataraj S, Imai N, Jungbluth AA, Tsakos I, Rahman A, Mei AH, Singh H, Zarychta K, Kim-Schulze S, Park A, Venhaus R, Alpaugh K, Gnjatic S, Cho HJ.: Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine–Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma Cancer Immunology Research 7 (4): 658-669,2019.

Trudel, S, Lendvai, N, Popat, R, Voorhees, P M., Reeves, B, Libby, E N., Richardson, P G., Hoos, A, Gupta, I, Bragulat, V, He, Z, Opalinska, J B., Cohen, A D.: Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study Blood Cancer Journal 9 (4): 37,2019.

Garfall A, Dancy E, Cohen A, Wang WH, Frai J, Suhoski M, Levine B, Siegel D, Stadtmauer E, Vogl D, Waxman A, Rapoport A, Milone M, June C, Melenhorst J: T cell phenotypes associated with effective CAR T cell therapy in post-induction versus relapsed multiple myeloma Blood Advances : 2019.

L Bernabei, A L. Garfall, J. J Melenhorst, S F Lacey, E A. Stadtmauer, D T. Vogl, V Gonzalez, G Plesa, R M Young, A Waxman, B L Levine, C H June, M C. Milone, and A D. Cohen: PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after BCMA-Directed CAR T Cells Blood, ASH Annual Meeting, San Diego, CA 132 : #1973,2018.

A.D. Cohen: CAR T-cell therapy against B-cell maturation antigen in multiple myeloma Clinical Advances in Hematology and Oncology 16 (12): 804-806,2018.

Academic Contact Info

Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-175
3400 Civic Center Blvd


Philadelphia, PA 19104
Phone: (215) 615-5853
Patient appointments: 800-789-7366 (PENN)